REVERSE-IT is PhaseBio’s ongoing pivotal Phase 3 trial of its lead product bentracimab, which is designed to study the reversal of the antiplatelet effects of ticagrelor in patients who present either ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback